MSFT 429.615 -0.3167% AAPL 240.32 0.3047% NVDA 139.4 0.5554% GOOGL 171.825 0.1953% GOOG 173.39 0.237% AMZN 211.2705 0.266% META 594.855 0.3416% AVGO 167.49 0.5886% TSLA 354.0867 -0.841% TSM 195.79 0.715% LLY 809.885 1.2609% V 313.24 -1.0769% JPM 247.365 0.4528% UNH 606.6797 -0.3024% NVO 110.44 1.6288% WMT 92.555 -0.0918% LVMUY 127.67 0.1333% XOM 117.962 0.095% LVMHF 640.0 -0.039% MA 528.05 -0.6229%
Last update at 2024-12-03T16:48:00Z
Why Henry Schein (HSIC) Could Beat Earnings Estimates Again
Fri 18 Oct 24, 04:10 PMHenry Schein Stock Gains From Dental Business Expansion Amid Macro Woe
Fri 18 Oct 24, 03:34 PMHenry Schein Opens Customer Assistance Hotline Ahead of Hurricane Milton
Tue 08 Oct 24, 09:33 PMHenry Schein Opens Customer Assistance Hotline Ahead of Hurricane Helene
Thu 26 Sep 24, 07:00 PMHenry Schein Named to FORTUNE® Magazine’s ‘Change the World’ List
Wed 25 Sep 24, 11:30 AMHenry Schein to Serve as Exclusive Distributor of Curodont to Dental Service Organizations
Tue 17 Sep 24, 10:30 AMHenry Schein Participates in the FDI World Dental Congress 2024 in Istanbul, Turkey
Thu 12 Sep 24, 10:30 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 721.00M | 830.55M | 499.89M | 680.31M | 695.35M |
| Minority interest | 28.00M | 29.29M | 15.63M | -24.77000M | 26.25M |
| Net income | 538.00M | 631.23M | 403.79M | 520.79M | 535.88M |
| Selling general administrative | 2771.00M | 2812.66M | 2246.95M | 2357.92M | 2217.27M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 3831.00M | 3672.25M | 2814.34M | 3090.89M | 3595.08M |
| Reconciled depreciation | 212.00M | 209.53M | 185.54M | 184.94M | 207.56M |
| Ebit | 747.00M | 851.66M | 535.30M | 718.26M | 914.29M |
| Ebitda | 1108.00M | 1075.62M | 758.90M | 930.75M | 1121.85M |
| Depreciation and amortization | 361.00M | 223.96M | 223.60M | 212.49M | 207.56M |
| Non operating income net other | 33.00M | 33.82M | 19.89M | 217.51M | 43.35M |
| Operating income | 747.00M | 851.66M | 535.30M | 718.26M | 753.05M |
| Other operating expenses | 11769.00M | 11541.43M | 9551.75M | 9252.84M | 12308.79M |
| Interest expense | 44.00M | 27.60M | 41.38M | 50.79M | 78.79M |
| Tax provision | 170.00M | 197.35M | 95.37M | 159.51M | 155.49M |
| Interest income | 17.00M | 6.45M | 9.84M | 15.76M | 21.24M |
| Net interest income | -27.00000M | -21.14900M | -31.53500M | -35.03500M | -57.55000M |
| Extraordinary items | - | - | - | -5.95700M | 116.84M |
| Non recurring | - | 7.94M | 32.09M | 14.71M | 101.40M |
| Other items | - | - | - | - | - |
| Income tax expense | 170.00M | 197.35M | 95.37M | 159.51M | 155.49M |
| Total revenue | 12647.00M | 12401.02M | 10119.14M | 9985.80M | 13202.00M |
| Total operating expenses | 2953.00M | 2812.66M | 2246.95M | 2357.92M | 2701.88M |
| Cost of revenue | 8816.00M | 8728.77M | 7304.80M | 6894.92M | 9606.91M |
| Total other income expense net | -26.00000M | -21.10800M | -35.40800M | -37.95400M | -140.31000M |
| Discontinued operations | - | - | 0.99M | -6.32300M | 105.16M |
| Net income from continuing ops | 566.00M | 660.53M | 418.44M | 725.46M | 539.86M |
| Net income applicable to common shares | 538.00M | 631.23M | 403.79M | 694.73M | 535.88M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 10573.00M | 8607.00M | 8481.09M | 7772.53M | 7151.10M |
| Intangible assets | 916.00M | 587.00M | 667.63M | 479.43M | 572.88M |
| Earning assets | - | - | - | - | - |
| Other current assets | 639.00M | 466.00M | 413.10M | 432.94M | 445.36M |
| Total liab | 5420.00M | 3936.00M | 4417.90M | 3788.15M | 3520.96M |
| Total stockholder equity | 3655.00M | 3446.00M | 3425.13M | 3348.17M | 2998.04M |
| Deferred long term liab | - | 36.00M | 42.28M | 30.07M | 64.99M |
| Other current liab | 1080.00M | 1038.00M | 1115.02M | 1029.53M | 958.93M |
| Common stock | 1.00M | 1.00M | 1.37M | 1.43M | 1.43M |
| Capital stock | 1.00M | 1.00M | 1.37M | 1.43M | 1.43M |
| Retained earnings | 3860.00M | 3678.00M | 3595.23M | 3454.83M | 3116.22M |
| Other liab | - | 397.00M | 418.95M | 422.85M | 396.16M |
| Good will | 3875.00M | 2893.00M | 2854.15M | 2504.39M | 2462.49M |
| Other assets | - | 232.00M | 190.41M | 149.41M | 120.81M |
| Cash | 171.00M | 117.00M | 117.97M | 421.19M | 106.10M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 2683.00M | 2224.00M | 2306.51M | 2283.10M | 2038.37M |
| Current deferred revenue | 89.00M | - | - | - | 64.99M |
| Net debt | 2570.00M | 1380.00M | 1098.72M | 581.23M | 892.25M |
| Short term debt | 494.00M | 182.00M | 137.56M | 247.92M | 199.17M |
| Short long term debt | 414.00M | 109.00M | 61.17M | 183.20M | 133.82M |
| Short long term debt total | 2741.00M | 1497.00M | 1216.68M | 1002.42M | 998.35M |
| Other stockholder equity | - | -233.00000M | 1.37M | 1054.31M | 47.77M |
| Property plant equipment | - | 667.00M | 366.46M | 342.00M | 329.64M |
| Total current assets | 4488.00M | 3988.00M | 3844.03M | 3791.41M | 3226.50M |
| Long term investments | 180.00M | 472.00M | 423.87M | 366.44M | 327.92M |
| Net tangible assets | - | 542.00M | 516.66M | 692.05M | 249.93M |
| Short term investments | - | - | - | - | - |
| Net receivables | 1863.00M | 1442.00M | 1451.83M | 1424.79M | 1246.25M |
| Long term debt | 1937.00M | 1040.00M | 811.35M | 515.77M | 622.91M |
| Inventory | 1815.00M | 1963.00M | 1861.14M | 1512.50M | 1428.80M |
| Accounts payable | 1020.00M | 1004.00M | 1053.93M | 1005.65M | 880.27M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | 649.00M | 638.07M | 636.21M | 632.09M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -206.00000M | -233.00000M | -171.47800M | -108.08400M | -167.37300M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 1.00M | 1.37M | 1.43M | 1.43M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 3678.00M | 3595.23M | 3454.83M | 3116.22M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 209.00M | 223.00M | -34.60700M | 154.47M | -23.62500M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 6085.00M | 4619.00M | 4637.06M | 3981.12M | 3924.60M |
| Capital lease obligations | 390.00M | 348.00M | 344.17M | 303.44M | 241.62M |
| Long term debt total | - | 1040.00M | 811.35M | 515.77M | 622.91M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 11.00M | 5.67M | 12.78M | 323.96M | -24.70000M |
| Change to liabilities | -96.00000M | 84.71M | 224.27M | 160.85M | 241.65M |
| Total cashflows from investing activities | -276.00000M | -677.21700M | -115.01900M | -424.37300M | -192.95400M |
| Net borrowings | 259.00M | 161.43M | -68.99300M | -1188.50600M | 297.20M |
| Total cash from financing activities | -315.00000M | -332.95700M | -187.18500M | -215.98000M | -603.77600M |
| Change to operating activities | -52.00000M | 9.06M | -6.47900M | -57.29100M | -165.64500M |
| Net income | 566.00M | 660.53M | 419.42M | 719.14M | 562.13M |
| Change in cash | -1.00000M | -303.22000M | 315.09M | 49.21M | -94.44900M |
| Begin period cash flow | 118.00M | 421.19M | 106.10M | 56.88M | 174.66M |
| End period cash flow | 117.00M | 117.97M | 421.19M | 106.10M | 80.21M |
| Total cash from operating activities | 602.00M | 709.58M | 598.91M | 654.09M | 684.71M |
| Issuance of capital stock | - | 0.00000M | - | 361.09M | - |
| Depreciation | 212.00M | 209.53M | 185.54M | 184.94M | 207.56M |
| Other cashflows from investing activities | -191.00000M | -603.86900M | -78.96700M | -672.11800M | -77.61700M |
| Dividends paid | - | - | - | -148.14600M | 17.52M |
| Change to inventory | -126.00000M | -295.13100M | -31.81700M | 14.70M | -84.78400M |
| Change to account receivables | -7.00000M | 4.16M | -189.34900M | -72.68900M | -147.49900M |
| Sale purchase of stock | -485.00000M | -401.21100M | -73.78900M | -525.00000M | -200.00000M |
| Other cashflows from financing activities | 229.00M | 208.93M | 497.82M | 1284.93M | -375.73400M |
| Change to netincome | 93.00M | 38.67M | 23.19M | -303.83000M | 8.37M |
| Capital expenditures | 96.00M | 79.02M | 48.83M | 76.22M | 90.64M |
| Change receivables | -7.00000M | 4.16M | -189.34900M | -72.68900M | -147.49900M |
| Cash flows other operating | -40.00000M | 7.11M | 387.08M | 670.11M | -102.70900M |
| Exchange rate changes | - | - | - | - | 17.57M |
| Cash and cash equivalents changes | 11.00M | -300.59400M | 296.71M | 13.73M | -94.44900M |
| Change in working capital | -281.00000M | -197.20100M | -3.37200M | 45.57M | -82.69600M |
| Stock based compensation | 54.00M | 78.42M | 8.79M | 44.92M | 36.24M |
| Other non cash items | 112.00M | -28.75600M | 66.39M | -338.37000M | 13.34M |
| Free cash flow | 506.00M | 630.57M | 550.08M | 577.87M | 594.07M |
Sector: Healthcare Industry: Medical Distribution
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HSIC Henry Schein Inc |
-0.69 0.90% | 75.81 | 24.12 | 14.04 | 0.74 | 2.50 | 0.95 | 13.33 |
| MCK McKesson Corporation |
2.30 0.37% | 623.59 | 17.95 | 14.53 | 0.20 | 5.04 | 0.22 | 12.17 |
| COR Cencora Inc. |
0.42 0.17% | 250.29 | 23.39 | - | - | - | ||
| CAH Cardinal Health Inc |
-0.035 0.03% | 122.44 | 166.11 | 14.71 | 0.12 | 16.07 | 0.12 | 19.78 |
| SHPMF Shanghai Pharmaceuticals Holding Co. Ltd |
-0.0001 0.0079% | 1.27 | 7.71 | 5.45 | 0.03 | 0.57 | 0.03 | 0.88 |
Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
135 Duryea Road, Melville, NY, United States, 11747
| Name | Title | Year Born |
|---|---|---|
| Mr. Stanley M. Bergman | Exec. Chairman & CEO | 1950 |
| Mr. James P. Breslawski | Exec. Vice Chairman & Pres | 1954 |
| Mr. Steven Paladino | Exec. Director | 1957 |
| Mr. Mark E. Mlotek | Exec. VP, Chief Strategic Officer & Exec. Director | 1956 |
| Mr. Ronald N. South | Sr. VP & CFO | 1962 |
| Mr. Michael Saul Ettinger | Exec. VP & COO | 1961 |
| Ms. Olga Timoshkina | VP of Corp. Fin., Chief Accounting Officer & Corp. Controller | NA |
| Mr. Christopher Pendergast | Sr. VP & CTO | 1964 |
| Graham Stanley | VP of Investor Relations & Strategic Fin. Project Officer | NA |
| Mr. Walter Siegel | Sr. VP & Chief Legal Officer | 1960 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...